CTI OPAXIO™ Receives Orphan Drug Designation for Malignant Brain Cancer from FDA

News   Oct 09, 2012

 
CTI OPAXIO™ Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
 
 
 

RELATED ARTICLES

Children With Congenital Zika Virus Infection Face Serious Challenges as They Age

News

The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.

READ MORE

Anti-Stress Compound Reduces Obesity and Diabetes

News

Researchers find a stress protein found in muscle has a diabetes promoting effect

READ MORE

British Pharmacological Society’s Drug Discovery of the Year 2018 Announced

News

A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE